A deep-dive analysis for pharma/biotech IP teams, R&D leads, and institutional investors.
Introduction: How a Single Negotiation Rewires a Drug’s Entire Commercial Lifecycle
The pharmaceutical industry runs on negotiation. Not the handshake kind, and not the zero-sum theater of positional bargaining taught in business school seminars. The negotiations that move capital, redirect R&D pipelines, and determine whether a patient can afford a medicine are technical, protracted, and deeply interdependent — each one shaped by regulatory history, patent architecture, payer leverage, and legislative reality.
Every approved drug passes through at least four discrete negotiation arenas before it generates a dollar of sustainable revenue. It begins with price and reimbursement, where the manufacturer faces off against payers, Pharmacy Benefit Managers (PBMs), and, since 2023, the federal government itself. It continues through M&A and licensing deals, where the IP embedded in that drug is priced, transferred, or partnered out. It proceeds through Health Technology Assessment (HTA) reviews in major markets. It ends, often years later, at the patent cliff, where generics and biosimilars restructure the entire commercial equation in a matter of months.
The average capitalized cost to develop a single approved drug reached $2.23 billion in 2024, per Deloitte’s annual analysis. That figure sets the floor for every pricing negotiation, every licensing demand, and every acquisition multiple. It explains why manufacturers set launch prices where they do, why PBMs can extract nine-figure rebate pools, and why the Inflation Reduction Act’s (IRA) negotiation program — the first direct federal price-setting mechanism in Medicare’s history — sent shockwaves through every DCF model on Wall Street.
This pillar document dissects the full negotiation ecosystem with the granularity that IP teams, deal lawyers, R&D leads, and institutional investors require. It goes beyond describing what happens at each negotiating table and explains precisely how value is created, allocated, and eroded across a drug’s entire lifecycle.
Section 1: The Arena and the Players — Mapping the Negotiation Ecosystem
1.1 The Stakeholder Matrix: Power, Motive, and Leverage
Pharmaceutical negotiations do not occur in bilateral isolation. They happen inside a crowded web of interdependencies where a decision made by one actor — the FDA approving a new indication, a PBM restructuring its national formulary, a court invalidating a key patent — cascades through every other relationship in the chain. Understanding who sits at which table, what they want, and what they can do if they don’t get it is the precondition for any effective strategy.
Manufacturers hold the initial pricing authority for any patented drug. Their R&D investments, which run $1.5 billion to $2.5 billion per approved asset depending on therapeutic class and clinical complexity, are the economic justification for the market exclusivity that patent protection provides. Their primary leverage is clinical differentiation: a drug with a clean Phase III dataset showing superiority over an existing standard of care has far more pricing power than one that demonstrated only non-inferiority. The molecule is the asset; the label is the monetization document.
Payers — private commercial insurers, self-funded employers, and government programs such as Medicare and Medicaid — bear the financial cost of the drugs their covered populations use. Their leverage is access denial: a manufacturer whose drug is excluded from a major formulary loses billions in potential revenue. Large government payers — CMS controls drug spending for over 67 million Medicare beneficiaries — can exercise monopsony-level pressure. Their primary constraint is their budget cycle, and their primary analytical tool is the cost-effectiveness threshold, typically expressed as a cost-per-quality-adjusted life year (QALY) ratio.
Pharmacy Benefit Managers are the most structurally powerful intermediaries in the U.S. market. The three largest — Express Scripts (part of Evernorth/Cigna), CVS Caremark, and OptumRx (part of UnitedHealth Group) — process roughly 79% of all U.S. prescription claims. This concentration gives them a near-monopsony position in rebate negotiations. They design formularies, set tier placements, administer prior authorization programs, and retain a portion of the rebates they extract from manufacturers as profit. The opacity of that profit — the ‘spread’ between what they charge payers and what they reimburse pharmacies — has become a focus of both congressional scrutiny and ongoing FTC investigations.
Healthcare providers sit at the prescribing interface, but their autonomy is constrained by formulary design, step therapy mandates, and prior authorization requirements. Their clinical judgment matters enormously in therapeutic categories with limited existing standards of care or where patient physiology varies widely. In oncology and rare disease, where physicians can document the failure of required alternatives as a purely administrative step, prior authorization requirements carry less actual clinical weight than in primary care.
Patient advocacy organizations wield network power that is disproportionate to their organizational size. The FDA’s Breakthrough Therapy designation program, PRIME at the EMA, and CMS’s IRA negotiation listening sessions all formally incorporate patient input. An organized advocacy community that can credibly demonstrate a drug’s transformative effect on quality of life — and can communicate that directly to a congressional committee or an HTA body — is a strategic asset manufacturers are right to cultivate early in clinical development.
Wholesalers — AmerisourceBergen (rebranded Cencora), McKesson, and Cardinal Health collectively control roughly 90% of U.S. drug distribution — operate on 1-3% margins but sit on the data that reveals actual dispensing volumes, geography, and channel mix. That data is commercially significant and increasingly central to real-world evidence (RWE) generation strategies.
1.2 A Framework for Analyzing Stakeholder Power
Power in pharmaceutical negotiations takes four distinct forms, and no party holds all of them simultaneously. Mapping a counterparty’s power profile before entering a negotiation is basic preparation that most negotiating teams still underestimate.
Positional power derives from formal authority. The FDA’s power to grant or withhold drug approval is absolute positional power. CMS’s authority under the IRA to set a Maximum Fair Price (MFP) is positional power backed by statute. A PBM’s contractual right to design its clients’ formularies is positional power at a commercial scale.
Economic power is the capacity to deploy or withhold financial resources. A manufacturer with a $40 billion balance sheet can sustain a period of reduced reimbursement; a single-product biotech cannot. A PBM that controls access to 30 million commercially insured lives can shift hundreds of millions in market share between competing products in a single formulary cycle.
Informational power is underrated and asymmetrically distributed. Manufacturers generate proprietary Phase III datasets, but payers hold real-world claims data showing actual patient outcomes and total cost of care. The party that can generate, credibly interpret, and effectively communicate superior data — whether about clinical outcomes, budget impact, or patent validity — holds a structural advantage at the negotiating table.
Network power is the ability to build coalitions, shape public perception, and mobilize political pressure. PhRMA’s lobbying apparatus operates on this dimension continuously. Patient groups that successfully pressured CMS to grant breakthrough designations or expedited reviews have demonstrated network power that reshaped timelines and, by extension, valuation trajectories for the drugs involved.
Assessing a stakeholder’s stance — whether they support, oppose, or are indifferent to a specific negotiating objective — is as important as mapping their power sources. A government payer with strong positional and economic power but whose policy staff are indifferent to a specific drug category is a less formidable counterparty than a commercially concentrated PBM that has identified that drug as a high-leverage formulary management opportunity.
1.3 The Regulatory Gauntlet: How the FDA and EMA Shape the Playing Field Before Negotiations Start
Regulatory agencies don’t negotiate prices. They do something more consequential: they define the asset that gets priced. The scope of a drug’s approved label, the population it covers, the claims it can make about efficacy and safety — these regulatory outputs are the raw material of every subsequent commercial negotiation.
The FDA label as negotiating asset. A broad approval covering a large, well-defined patient population with a strong efficacy claim — measured in overall survival, not just a surrogate endpoint — gives a manufacturer an immensely defensible position in both pricing negotiations and HTA reviews. A narrow approval restricted to a heavily biomarker-selected subpopulation reduces the addressable commercial market and requires manufacturers to make more conservative pricing arguments. Every word in an approved indication statement has economic consequence.
Breakthrough Therapy designation and its evidence paradox. The FDA’s Breakthrough Therapy program, established under the FDA Safety and Innovation Act of 2012, is designed to accelerate development of drugs for serious conditions where preliminary clinical evidence shows substantial improvement over available therapy. Between its establishment and 2024, the FDA granted Breakthrough designation to hundreds of drugs, and the program has broadly achieved its timeline-compression objective. The strategic tension is real, though: a compressed development timeline can mean Phase III trials are completed with fewer events, shorter follow-up periods, and limited comparative effectiveness data. A drug approved on the basis of an 18-month progression-free survival readout in a single-arm trial faces a far more skeptical HTA review than one with five-year overall survival data in a randomized head-to-head study. Speed to approval is not the same as strength of evidence for value negotiations.
PRIME, EMA, and the European evidence gap. The EMA’s PRIority MEdicines (PRIME) scheme mirrors the Breakthrough Therapy concept but reflects a different regulatory philosophy. The EMA has historically required new drugs to demonstrate benefit against an active comparator — the existing standard of care — rather than placebo. This means drugs developed primarily for FDA approval, which can rely on placebo-controlled trials, sometimes arrive at EMA review with a clinical package that does not directly answer the comparative question European HTA bodies ask. Generating placebo-controlled Phase III data in a context where an effective standard of care exists is, in many therapeutic areas, now ethically contested. The resulting evidence gap is a structural drag on European pricing negotiations.
The transatlantic pricing corridor. The U.S. launch is, by deliberate strategic design, almost always the first launch for a new drug. The FDA’s review timelines are faster than the EMA’s on average, and the U.S. market is the only major market without a statutory price cap at launch. By establishing a high Wholesale Acquisition Cost (WAC) in the U.S. first, manufacturers create a public price anchor. European health ministries and HTA bodies then negotiate against that reference point, which is politically useful for manufacturers even when European net prices end up far below the U.S. WAC. This sequencing is not accidental; it is a pre-negotiation tactic executed years before European submissions are filed.
Regulatory harmonization: real and limited. The FDA and EMA reached roughly 92% concordance in approval decisions across a 2014-2016 study period. Their mutual recognition agreements (MRAs) for Good Manufacturing Practice (GMP) inspections reduce duplicative site audits. But on the core questions that matter for negotiation — what comparator trial data is required, how surrogate endpoints are weighted, what real-world evidence can substitute for randomized trial data — the two agencies remain meaningfully divergent. Companies building global clinical development programs for high-value assets must satisfy both, which inflates trial complexity and cost, and sets the evidentiary baseline for all downstream price and HTA negotiations.
Key Takeaways — Section 1
The stakeholder matrix in pharmaceutical negotiations is not static. Regulatory decisions cascade through the entire commercial ecosystem: a broad FDA label amplifies manufacturer pricing power, which the PBM then converts into larger rebate demands, which the payer converts into formulary leverage, and so on down the chain. Mapping each actor’s power profile before any negotiation — not just the most visible counterparty — is the minimum required preparation.
Investment Strategy — Section 1
For institutional investors evaluating pharma assets, the quality of the FDA label is a leading indicator of future pricing power and HTA success, both of which flow through to long-term revenue sustainability. Assets approved with overall survival data in large, unselected populations carry materially lower commercial risk than those approved on surrogate endpoints in biomarker-enriched subpopulations. Breakthrough Therapy designation is a positive signal for timeline; it is not a signal about evidence quality for payer negotiations.
Section 2: The Price Negotiation Battlefield — From PBM Rebates to the IRA’s Maximum Fair Price
2.1 The Gross-to-Net Bubble: Anatomy of a $356 Billion Distortion
The gap between what a pharmaceutical manufacturer charges and what it actually receives — the ‘gross-to-net bubble’ — reached a record $356 billion in 2024. The Drug Channels Institute, which tracks this figure annually, reported that growth in the bubble slowed to its lowest rate in a decade, but the absolute dollar figure is larger than the annual GDP of Denmark.
The mechanics are straightforward. The WAC is the list price manufacturers set and publicly report. Every link in the distribution chain between that list price and the pharmacy shelf extracts a discount: PBM rebates negotiated in exchange for formulary placement, mandatory Medicaid rebates calculated as a percentage of WAC, 340B Drug Pricing Program discounts for covered entity purchasers, distribution fees, prompt-pay discounts, and chargebacks from wholesalers. The net price — actual manufacturer revenue after all deductions — is the only figure that reflects true commercial economics.
The 2024 data from nine top manufacturers illustrates the distortion clearly. The unweighted average list price increase across major products was 3.8%, but the average net price increase was only 2.0%. For several companies, net prices declined in real terms even as list prices rose. This happens because PBMs have become increasingly effective at demanding rebates that grow faster than list price inflation. A drug with a 5% WAC increase and a renegotiated rebate that moves from 40% to 45% of WAC has a net price that is essentially flat.
The counterintuitive insulin dynamic illustrates how perverse this system has become. When Eli Lilly, Novo Nordisk, and Sanofi announced major list price cuts for their insulin products in 2023-2024, some manufacturers saw their Medicaid net prices actually rise on certain volumes. This is because Medicaid’s basic rebate is calculated as the greater of 23.1% of AMP (Average Manufacturer Price) or the difference between AMP and the lowest price charged. A dramatic list price cut can, under specific formulaic conditions, compress the rebate obligation and improve net. This anomaly does not make list price cuts bad policy, but it demonstrates that the gross-to-net system contains incentive structures that are almost impossible to fully anticipate.
2.2 PBM Architecture: Tactics, Leverage, and the Market Concentration Problem
The three largest PBMs — Express Scripts, CVS Caremark, and OptumRx — collectively process approximately 79% of U.S. prescription claims. Each is vertically integrated with a parent insurer or health system. Express Scripts is owned by Cigna (through its Evernorth subsidiary). CVS Caremark is part of CVS Health, which also owns the Aetna insurer. OptumRx is part of UnitedHealth Group, which also owns the UnitedHealthcare insurance business. This vertical integration means the three largest PBMs also happen to be affiliated with three of the largest commercial health insurers in the country, a structural concentration of leverage that the FTC has scrutinized in ongoing investigations.
Formulary management as primary leverage. The three-tier formulary structure — preferred, non-preferred, and excluded — is the PBM’s primary instrument of market control. A drug on Tier 2 (preferred brand) with a $40 copay will capture substantially more market share than the same drug on Tier 3 (non-preferred) with a $120 copay, even if the clinical profiles are identical. Manufacturers bid for preferred placement with rebate commitments. In highly competitive therapeutic categories — SGLT-2 inhibitors, GLP-1 receptor agonists, TNF inhibitors — PBMs run structured bidding processes that closely resemble auction mechanisms, explicitly pitting Jardiance against Farxiga, or Ozempic against Mounjaro, to extract maximum concessions.
Rebate contracting structure. Rebates are typically structured in several tranches: a base rebate paid unconditionally, a performance rebate tied to market share thresholds, and sometimes a formulary compliance rebate tied to maintaining preferred status for a specified period. The market share tranches create a compounding incentive structure: once a drug crosses a specified market share threshold, the per-unit rebate increases retroactively for all units dispensed in that period. This makes it financially rational for a PBM to aggressively promote a rebated drug even if a competitor drug has a lower net cost.
Spread pricing and its political fallout. Spread pricing — retaining the difference between what a PBM charges a health plan and what it pays a pharmacy for the same drug — is most prevalent in Medicaid managed care and state employee benefit programs, where oversight has historically been weakest. A 2023 House Oversight Committee report documented cases where PBMs charged state Medicaid programs prices that were hundreds of percent above the pharmacy acquisition cost. Multiple states have since enacted spread pricing transparency requirements, and CMS issued guidance in 2024 requiring greater disclosure in Medicaid managed care PBM contracting.
Utilization management as formulary enforcement. Prior authorization, step therapy, and quantity limits are not primarily clinical tools. They are formulary enforcement mechanisms. A step therapy protocol that requires a patient to try and fail on Drug A before the PBM will cover Drug B is, in practice, a method of directing patients toward the drug for which the PBM has a superior rebate arrangement. The clinical justification may exist — trying a less expensive, established therapy before a newer one is often good medicine — but the protocol design frequently reflects the commercial arrangement rather than clinical evidence.
Group Purchasing Organizations and offshore opacity. Some PBMs participate in GPOs that aggregate purchasing across multiple entities to demand steeper manufacturer discounts. The most controversial of these are structured offshore, in jurisdictions with limited financial transparency requirements, making it difficult for manufacturers or health plans to determine the actual terms of these arrangements. The House Oversight Committee’s 2024 report specifically identified this structure as a mechanism for opaque profit extraction that is difficult to audit.
2.3 The IRA Paradigm: Mechanics of the Medicare Price Negotiation Program
The Inflation Reduction Act of 2022 ended a 19-year prohibition on direct Medicare drug price negotiation. The Medicare Modernization Act of 2003 had included an explicit ‘non-interference’ clause barring the HHS Secretary from negotiating prices for Part D drugs. Section 11001 of the IRA repealed that prohibition, establishing the Medicare Drug Price Negotiation Program with a defined process, a defined eligible population of drugs, and a defined ceiling on the resulting Maximum Fair Price.
Eligibility criteria and selection logic. A drug qualifies for the IRA negotiation pool if it is a Qualifying Single Source Drug (QSSD): it has FDA approval, faces no approved generic or biosimilar competitors, and has been on the market for at least seven years (small-molecule drugs) or eleven years (biologics). CMS selects from this pool based on total Medicare gross spending, targeting the drugs that cost Medicare the most in aggregate. The program began with 10 Part D drugs for 2026 applicability, added 15 drugs for 2027, and is set to add 20 drugs annually from 2028 onward. A separate track covering Part B drugs — physician-administered biologics and injectables — begins with 2028 applicability.
The negotiation process mechanics. After CMS identifies selected drugs each September and manufacturers confirm participation by October, the formal process runs from February through August of the following year. CMS issues an initial MFP offer by June 1. The manufacturer has 30 days to counteroffer. A series of negotiation meetings follows, with CMS required to produce a final MFP by August 1. CMS must provide written justification for its final offer, documenting how it weighted R&D costs, manufacturing costs, prior federal financial support for the drug’s development, and the clinical benefit relative to existing therapies.
The statutory MFP ceiling. The IRA’s MFP ceiling is a percentage of the drug’s non-federal average manufacturer price (non-FAMP), adjusted by how long the drug has been on the market: for a drug that has been approved for 7-11 years, the MFP ceiling is 75% of non-FAMP (a 25% discount). For drugs on the market 11-15 years, the ceiling is 65% of non-FAMP (a 35% discount). For drugs on the market more than 15 years, it is 40% of non-FAMP (a 60% discount). These ceilings represent the maximum the MFP can be, not the expected outcome — CMS can negotiate further below the ceiling.
The ‘non-negotiation’ problem. A manufacturer’s practical options when selected are three: negotiate and accept the MFP, refuse and pay an excise tax starting at 65% of U.S. drug revenues and escalating to 95% within six months, or withdraw all products from Medicare and Medicaid coverage. No major company has chosen options two or three, which means the process functions as mandatory price-setting with a structured exchange of cost and clinical data as procedural context. Critics across the political spectrum — from pharma executives to health economists at USC’s Schaeffer Center — have argued that calling this process a ‘negotiation’ is more politically useful than technically accurate.
2.4 First-Round Data: What Actually Happened with Stelara, Enbrel, and Imbruvica
The 10 drugs selected for the first IRA negotiation cycle, with 2026 price applicability, were: Eliquis (apixaban, BMS/Pfizer), Jardiance (empagliflozin, Boehringer Ingelheim/Lilly), Xarelto (rivaroxaban, J&J/Bayer), Januvia (sitagliptin, Merck), Farxiga (dapagliflozin, AstraZeneca), Entresto (sacubitril/valsartan, Novartis), Enbrel (etanercept, Amgen), Imbruvica (ibrutinib, AbbVie/J&J), Stelara (ustekinumab, J&J), and Fiasp/NovoLog insulin (Novo Nordisk).
The Brookings Institution’s analysis of the final MFPs is the most granular publicly available. The projected Medicare savings through 2033 from these 10 drugs total approximately $18.6 billion. On an annual basis using 2023 prescription volumes, CMS estimated $6 billion in immediate savings. The average MFP across the 10 drugs was approximately 22% below the prior net price — meaning the IRA delivered an additional 22% cut beyond what PBM rebate negotiations had already achieved.
The distribution of those savings was highly uneven, and the pattern reveals the IRA’s underlying logic. Stelara, Enbrel, and Imbruvica received the largest discounts from the IRA process. These were precisely the drugs that had faced the least competitive pressure in the pre-IRA environment — Enbrel had been blocked from biosimilar competition for years by patent litigation, and Stelara held a dominant position in the IL-12/23 inhibitor market with limited head-to-head competition. In contrast, drugs already in competitive markets — Jardiance, Januvia, Farxiga — received smaller incremental discounts from the IRA because PBMs had already extracted substantial rebates through competitive formulary management.
IP Valuation: J&J’s Stelara (ustekinumab)
Stelara’s IP position at the time of IRA selection illustrated both the value and the vulnerability of a narrow-target biologic franchise. The core ustekinumab molecule patent expired in September 2023 in the U.S. Several biosimilar makers, including Amgen (Wezlana), Samsung Bioepis, and Sandoz, received FDA approvals in rapid succession through 2023-2024. The commercial launch of biosimilars, combined with the IRA’s MFP kicking in January 2026, created a compounding revenue compression event for J&J. Stelara generated $10.1 billion in global revenue in 2022; the combined biosimilar entry and MFP has driven meaningful volume and price erosion. For J&J’s IP team, the Stelara situation represents a clean case study of what happens when a biologic’s patent fortress is breached just before the IRA eligibility window closes — the asset loses pricing power from two directions simultaneously.
IP Valuation: AbbVie/J&J’s Imbruvica (ibrutinib)
Imbruvica’s IP situation is more complex. The drug has more than 165 patents in the Orange Book, covering not just the ibrutinib molecule but its formulations, combinations, methods of use, and manufacturing processes — a textbook patent thicket. Despite this, the IRA negotiation produced a significant MFP reduction from Imbruvica’s prior net price, and a competitive threat has emerged from next-generation BTK inhibitors including AstraZeneca’s Calquence (acalabrutinib) and BeiGene’s Brukinsa (zanubrutinib), the latter of which has demonstrated superior tolerability data in head-to-head trials. For AbbVie, Imbruvica’s IP estate is now primarily defensive — focused on extending exclusivity long enough for its successor BTK inhibitor, pirtobrutinib (Jaypirca, acquired via the $21 billion Pharmacyclics deal’s residual IP), to capture the market. The lesson for IP strategists: a 165-patent thicket around a small molecule does not prevent an IRA selection, nor does it insulate against a clinically superior next-generation competitor.
IP Valuation: Amgen’s Enbrel (etanercept)
Enbrel occupies a singular position in American pharmaceutical history. The drug is approved for rheumatoid arthritis, psoriatic arthritis, and psoriasis. Pfizer, which co-commercializes the drug, and Amgen, which manufactures it, built and maintained a patent estate that effectively blocked biosimilar entry in the U.S. for over five years after the core molecule patent expired in 2028 (with additional patent protection through a manufacturing process patent expiring as late as 2029). In Europe, the same drug — Benepali (Samsung Bioepis) and Erelzi (Sandoz) — launched as biosimilars in 2016 and captured substantial market share within two years. The U.S. market saw no commercially launched Enbrel biosimilar until Erelzi (Sandoz) and others moved in 2024 after patent settlements. The delta between the European and U.S. competitive timelines, driven entirely by IP strategy, illustrates the hundreds of millions in additional revenue that a well-executed secondary patent program generates. The IRA’s MFP for Enbrel was negotiated against a backdrop where biosimilar competition was finally beginning; the government’s discount supplemented market forces that were only starting to exert pressure.
2.5 The ‘Pill Penalty,’ Portfolio Distortion, and the Launch Price Feedback Loop
The IRA’s seven-year small-molecule eligibility clock versus the eleven-year biologic clock is not a minor technical distinction. It is a structural incentive that will reshape pharmaceutical R&D investment allocations for the next decade. The four-year difference means a biologic approved in the same year as a small molecule will generate four additional years of unconstrained Medicare pricing before becoming subject to the MFP. In a standard discounted cash flow model at a 10% WACC, four additional years of full-price Medicare revenue for a blockbuster biologic generating $3 billion annually in Medicare is worth roughly $8-10 billion in NPV terms, depending on the discount rate and growth assumptions. That differential is now embedded in every acquisition valuation, every licensing term sheet, and every R&D portfolio prioritization meeting.
The IRA has also created a predictable launch price inflation incentive. With the MFP timeline now fixed and knowable at the time of FDA submission, manufacturers can calculate exactly how many years of unconstrained pricing they will receive before a government-mandated price cut. To maximize cumulative revenues before the MFP takes effect, the rational response is to set a higher initial WAC. The commercial insurance market — covering roughly 180 million Americans and not subject to IRA negotiations — absorbs this inflation. A policy designed to reduce drug costs for Medicare beneficiaries is therefore creating a mechanism for higher launch prices in the commercial market, a cross-market distortion that CMS’s design team either accepted as unavoidable or did not fully model.
Key Takeaways — Section 2
The gross-to-net bubble at $356 billion is both the symptom and the mechanism of the U.S. drug pricing system’s dysfunction. PBMs extract the largest share of this pool through formulary leverage that no single manufacturer can resist without accepting significant commercial damage. The IRA’s negotiation program targets the specific market failure — first-in-class drugs with no competitive pressure and limited pre-existing rebates — most effectively. The pill penalty creates a durable biologic premium that will bias M&A and licensing deal structures for years.
Investment Strategy — Section 2
The IRA’s MFP data for 2026 is now public. Investors holding positions in drugs scheduled for the 2027 and 2028 rounds should model the expected MFP using the statutory ceiling framework and Brookings’ observed discount rates from round one. For small-molecule assets within five years of their seven-year eligibility date, the present-value impact of the MFP should be factored into any DCF model. For biologic franchises with approaching 11-year windows, the question is whether biosimilar entry will precede or follow IRA selection — the combination of both, as Stelara experienced, produces the most severe revenue compression.
Section 3: Strategic Dealmaking — M&A, Licensing, and the IP Valuation Engine
3.1 M&A: Negotiating for Pipeline Replenishment Against the Patent Cliff
The ‘patent cliff’ is not metaphor. It is a calendar event, and pharmaceutical executive teams plan around it with the precision of bond portfolio managers managing duration risk. When a blockbuster drug loses exclusivity, revenue does not decline gradually. Generic entry, particularly for small molecules with multiple ANDA filers, can reduce brand market share by 80-90% within 12 months. Biosimilar entry for biologics is slower but moves in the same direction.
Merck’s situation with Keytruda (pembrolizumab) is the most-discussed patent cliff exposure in the industry as of 2025. Keytruda generated $25 billion in global sales in 2024 — roughly 40% of Merck’s total revenue — and faces U.S. patent expiration beginning around 2028, with core composition-of-matter patents expiring by 2029. Merck’s response has been multi-pronged: a $22 billion Prometheus Biosciences acquisition for autoimmune assets, a $10.8 billion Harpoon Therapeutics acquisition for bispecific antibody technology, and a subcutaneous formulation development deal with Alza/J&J technology partners to generate a new dosing form of pembrolizumab that could reset the regulatory exclusivity clock. The Keytruda patent situation is therefore driving acquisition valuations, R&D partnership terms, and clinical development priorities simultaneously — a live example of how patent architecture shapes corporate strategy at the highest level.
The broader 2024-2025 M&A market is characterized by a ‘string-of-pearls’ approach rather than mega-mergers. Deals in the $1-10 billion range dominate. Regulatory headwinds from an FTC that scrutinized several proposed mergers aggressively — including the Amgen/Horizon ($28 billion) deal, which closed only after Amgen accepted behavioral remedies in 2024 — have pushed acquirers toward smaller, lower-antitrust-risk targets. Policy uncertainty around IRA expansion, potential tariff impacts on API supply chains, and interest rate environments that inflate the cost of financing large acquisitions have collectively elevated risk premiums on deal valuations.
Earlier-stage deal activity has accelerated. Pre-clinical and Phase 1 targets captured a larger share of total M&A value in 2024 than in any year since 2018, per IQVIA’s deal database. This reflects a deliberate tolerance for scientific risk. When a Phase III asset with a clear clinical profile is available, every major acquirer at the same patent cliff timeline will bid for it, inflating the price. Earlier-stage assets carry more scientific uncertainty but less competitive bidding pressure, and for companies with strong internal development capabilities — J&J’s Janssen, Roche’s Genentech, and Pfizer’s internal oncology team — the science-to-commercial pipeline management is a differentiating capability.
3.2 IP Due Diligence: Where Valuation Is Won or Lost
In a pharmaceutical acquisition, the IP portfolio is not a component of the asset; it is the asset. The manufacturing facility, the clinical team, the commercial staff — all are replaceable. The patents, regulatory exclusivities, and trade secrets embedded in a drug candidate are not. This reality means that IP due diligence in a pharma M&A transaction is not a legal formality conducted by outside counsel in the final weeks before close. It is a valuation-determining analytical exercise that begins at the term sheet stage and continues throughout the negotiation.
Chain of title and ownership verification. Every patent in a drug’s portfolio traces back to an inventor assignment. If a researcher left the company before executing an assignment agreement, or if an assignment was never properly recorded at the USPTO, that patent’s title may be clouded. Title defects discovered post-close are expensive to remediate and may render key patents unenforceable. Diligence teams need access to the original assignment records, not just the prosecution file history.
Validity risk and prior art analysis. A patent’s nominal expiration date on a database is not the same as its commercial lifetime. Any patent can be challenged through inter partes review (IPR) at the USPTO Patent Trial and Appeal Board (PTAB), post-grant review (PGR), or through Paragraph IV ANDA/BPCIA certification challenges in district court. The statistical probability of IPR institution given a petition filing has been approximately 60-65% in recent years. Once instituted, roughly 70-75% of challenged claims are cancelled or amended. A diligence team needs to assess each key patent’s vulnerability to IPR or Paragraph IV challenge, not just its face validity.
Freedom-to-operate (FTO) analysis. An FTO analysis determines whether a drug’s manufacture, use, or sale would infringe valid in-force third-party patents. An incomplete FTO analysis in due diligence is among the most expensive errors in pharma deal-making. A drug that reaches the market only to face an injunction for patent infringement — a credible risk in crowded spaces like oncology kinase inhibitors or GLP-1 formulation chemistry — represents the worst possible post-close outcome. FTO analysis must cover not just the drug molecule but the manufacturing process, the formulation, the delivery device (for combination products), and any relevant biomarker companion diagnostic.
Regulatory exclusivity mapping. The commercial runway of a pharmaceutical asset is determined by whichever expires later: the last relevant patent, or the last applicable regulatory exclusivity period. A drug can have no remaining composition-of-matter patent protection but still be shielded from generic entry by a five-year New Chemical Entity (NCE) exclusivity, a three-year new clinical investigation exclusivity for a new formulation, or a seven-year Orphan Drug Exclusivity period. For pediatric extensions under PREA or the voluntary pediatric exclusivity program under BPCA, an additional six months can be added to any existing exclusivity. Mapping the full exclusivity stack — patents plus regulatory protections — is the foundation for any accurate DCF model of the asset’s revenue life.
Paragraph IV litigation exposure and settlement structures. For small-molecule drugs with existing ANDAs on file at FDA, the Orange Book is the starting map. If a drug has multiple ANDA filers with Paragraph IV certifications, patent litigation is likely underway or imminent. Each pending Paragraph IV case is a potential acceleration event for generic entry if the brand-side patents are found invalid or not infringed. An acquirer inheriting a drug with eight active Paragraph IV cases has a fundamentally different risk profile than one acquiring a drug with a clean Orange Book.
3.3 Evergreening Tactics: The Biologic Technology Roadmap
‘Evergreening’ — the practice of filing secondary patents around an existing drug to extend the effective period of market exclusivity beyond the core composition-of-matter patent’s expiration — has been deployed with extraordinary sophistication by innovator companies across both small-molecule and biologic franchises. For institutional investors, understanding the technology roadmap of an evergreening strategy is essential for modeling the actual commercial runway of a drug investment.
Secondary patent categories for small molecules include: crystalline polymorph patents (covering specific solid-state forms of the molecule that offer manufacturing or stability advantages); salt and ester patents (covering specific pharmaceutical forms such as sodium or potassium salts); formulation patents (covering specific dosing vehicles, excipients, or release profiles); method-of-treatment patents (covering specific patient populations, dosing regimens, or combination uses); and metabolite patents (covering the active metabolite of a prodrug). Each category has different legal vulnerability profiles. Polymorph patents are particularly susceptible to IPR challenge if the specific form lacks sufficient teaching in the specification.
Biologic patent thicket construction is more complex because the molecule itself — a large protein — is harder to replicate exactly, and the BPCIA’s ’12-year biologic exclusivity’ provides a statutory floor that small molecules lack. Biologic evergreening strategies focus on: formulation patents (covering specific concentrations, pH levels, or excipient compositions in the drug product); device patents for the auto-injector or pen delivery system (which can delay interchangeable biosimilar designation because the biosimilar must demonstrate device equivalence); manufacturing process patents (covering specific cell culture conditions, purification steps, or quality specifications); and combination therapy patents (covering use of the biologic with a specific small molecule).
AbbVie’s Humira (adalimumab) remains the most-studied example of biologic patent evergreening. AbbVie built a portfolio of over 130 patents around adalimumab covering formulation, concentration, citrate-free formulation, manufacturing, and delivery device. These patents were used to settle Paragraph IV ANDA-analog (BPCIA) challenges from Amgen, Samsung Bioepis, Sandoz, and others with delayed U.S. launch dates. Biosimilar competition in the U.S. did not begin until January 2023 — years after European biosimilar launches in 2018 — despite the core molecule patent’s earlier expiration. The revenue differential that AbbVie captured through that period is estimated in the tens of billions. The FTC has characterized similar evergreening strategies in recent enforcement actions as potentially anticompetitive, creating a new legal risk dimension that IP strategists must incorporate into thicket-building decisions.
The subcutaneous/intravenous reformulation tactic. Converting an intravenous drug to a subcutaneous formulation — or vice versa — can generate a new dosing form that qualifies for separate formulation patent protection and sometimes a new three-year clinical investigation exclusivity at FDA. Roche’s Tecentriq SC (subcutaneous atezolizumab) and Darzalex FASPRO (subcutaneous daratumumab, J&J) represent this tactic in practice. The subcutaneous formulation often also carries a clinical and commercial advantage — patient convenience, reduced chair time — that supports a premium pricing argument independent of the patent.
The indication expansion roadmap. Filing a Supplemental New Drug Application (sNDA) or Supplemental BLA for a new clinical indication can generate an additional three years of new clinical investigation exclusivity from the date of the supplemental approval. It also restarts the method-of-treatment patent clock for the new indication. For drugs with broad mechanism-of-action applicability — checkpoint inhibitors, JAK inhibitors, IL-cytokine blockers — the indication expansion roadmap can run for a decade post-initial approval, with each new approval potentially extending the effective IP-protected revenue life of the franchise.
3.4 Licensing and Collaboration Deal Architecture
Out-licensing and in-licensing are portfolio management tools with specific and distinct applications. Out-licensing converts a non-core asset into a capital event — upfront payment, milestones, royalties — without the overhead of full commercial development. In-licensing acquires access to a technology or drug candidate without paying the full acquisition premium for the parent company. Both are more capital-efficient than acquisition for targeted purposes, and both require rigorous IP and commercial diligence before terms are set.
Deal financial architecture. A standard licensing agreement in pharma has four financial components: the upfront payment, paid at signing; development milestones, triggered by clinical and regulatory events (Phase 2 completion, IND filing, NDA acceptance, FDA approval); commercial milestones, triggered by first commercial sale or net sales thresholds; and royalties, paid as a percentage of net sales for the life of the agreement. Market benchmarks from the Deloitte and HealthCare Royalty Partners annual surveys indicate that royalty rates in early-stage (pre-Phase II) deals typically run 6-12% of net sales, while late-stage (post-Phase III) deals command 15-25%, reflecting the risk-adjusted value of clinical proof. Upfront payments range from a few million dollars for early-stage academic licenses to several hundred million for post-Phase II platform deals.
Exclusivity scope, territory, and field-of-use definitions. The exclusivity provisions determine the commercial value of the license to the licensee. A worldwide exclusive license in all fields and indications is the maximum grant and commands the highest upfront payment. A non-exclusive license in a defined field and territory is worth far less. The field-of-use definition is particularly critical in platform technology licenses: a license to use a CRISPR delivery technology ‘for oncology indications’ must specify exactly which oncology applications are included, whether hematologic malignancies fall within that definition, whether the field covers CAR-T applications, and how field expansions will be priced if the licensee later identifies applications outside the original definition.
Sublicensing rights. The right to sublicense — to grant rights under the licensed IP to a third party, typically a regional commercial partner — is a negotiated point with significant economic consequence. A licensee who can sublicense in Asia can bring in a regional partner and recoup a portion of the upfront payment through sublicense fees, effectively reducing its net cost of acquisition. The licensor typically demands a share of any sublicensing income — between 20% and 50% of sublicense fees is conventional — and retains approval rights over the sublicensee to protect the IP’s integrity.
The strategic dis-integration of global portfolios. For large pharmaceutical companies managing assets across 50-plus markets, out-licensing in non-core territories has evolved from a revenue diversification tactic into a portfolio management discipline. A company with a primary commercial infrastructure in the U.S., Germany, France, UK, Japan, and China can out-license its drug’s rights in Latin America, Southeast Asia, and the Middle East to regional partners with established infrastructure. The licensor receives non-dilutive capital from upfront and milestone payments, offloads regulatory and commercial execution costs in those markets, and frees management attention for higher-priority geographies. This approach does carry risks: quality control in manufacturing and pharmacovigilance obligations must be contractually addressed to prevent the licensor’s FDA-registered brand from being compromised by a licensee’s actions in a distant market.
The IRA’s biologic premium in licensing terms. The four-year differential between small-molecule and biologic IRA eligibility is already appearing in licensing term sheets. A licensor of a biologic can support a higher upfront payment demand by pointing to the extended pre-MFP revenue runway that a DCF analysis will capture. Conversely, a licensee acquiring rights to a small-molecule asset with six years until its seven-year IRA eligibility window opens needs to model the MFP’s impact on the royalty base in its financial projections. For long-duration royalty agreements, this distinction can change the net present value of the royalty stream by hundreds of millions of dollars.
Key Takeaways — Section 3
IP due diligence is valuation. The price paid in any pharma M&A transaction is a bet on the defensibility of the target’s patent estate and the accuracy of its regulatory exclusivity mapping. Secondary patent construction — evergreening through formulation, device, method-of-treatment, and indication expansion — can extend a biologic’s effective exclusivity by years beyond the core molecule patent and is the primary reason the U.S. and European competitive timelines diverge so dramatically for the same drugs.
Investment Strategy — Section 3
Before any acquisition or licensing deal, commission an independent IP landscape report that covers: chain of title verification, Paragraph IV challenge exposure, PTAB IPR petition vulnerability for the top five revenue-generating claims, FTO against third-party patents in the relevant chemical space, and regulatory exclusivity mapping through 2035. Tools such as DrugPatentWatch, Derwent Innovation, and Clarivate Cortellis allow systematic tracking of Orange Book listings, patent expiry dates, and challenge histories. The cost of that analysis — typically $50,000-$300,000 depending on scope — is immaterial relative to the acquisition price. Not doing it is not a cost saving; it is a risk transfer to the acquirer.
Section 4: Market Access — The Last Mile and Its Gatekeepers
4.1 The Payer Gauntlet: Reimbursement Hurdles After Regulatory Approval
FDA approval opens the commercial door; it does not guarantee revenue. A Deloitte analysis found that 34% of new drug launches in the U.S. fail to meet pre-launch revenue expectations, and in more than half of those failures, inadequate market access — not poor clinical performance — was the primary driver. In the UK, NICE has historically rejected approximately 50% of drugs submitted for first appraisal at the manufacturer’s proposed price. In Germany, the AMNOG process has produced a finding of ‘no additional benefit’ for a substantial minority of new drugs, forcing manufacturers to accept reference-priced reimbursement for those products. Market access is not a post-approval administrative task; it is a commercial outcome that depends on strategic preparation that begins in Phase II trial design.
Commercial payer dynamics in the U.S. Each major commercial payer and their PBM partner conducts an independent formulary review for every new drug. A launch price that is high relative to a drug’s incremental clinical benefit will trigger formulary exclusion or Tier 3/non-preferred placement. A competitive category with multiple approved alternatives gives the PBM more leverage to demand a higher rebate in exchange for preferred placement. In specialty therapeutics — oncology, rare disease, neurology — formulary exclusion is less frequent because prescriber and patient advocacy dynamics create political pressure on payers, but utilization management through prior authorization is pervasive.
Step therapy as a market access barrier. Step therapy requirements force patients to try and fail on an earlier therapy — typically a less expensive generic or established brand — before the payer will cover a newer drug. For manufacturers of second-line or third-line treatments, step therapy can create a meaningful lag between approval and peak commercial penetration, as patients must cycle through required first-line agents before physicians can prescribe the new drug. In therapeutic areas where failure on first-line therapy causes clinical harm — certain cancers, autoimmune diseases with rapid progression — step therapy requirements are directly contested in prescriber education and payer policy advocacy.
4.2 HTA Bodies: NICE, G-BA, HAS — A Comparative Roadmap
The European HTA landscape requires a country-specific strategy for every major market. There is no single European formulary and no unified European pricing authority. The EU’s new HTA Regulation (2021/2282), which became applicable for oncology products in January 2025 and will extend to all new drugs by 2030, introduces a joint clinical assessment process through the HTA Coordination Group. Critically, the joint clinical assessment covers only the comparative clinical effectiveness review — relative efficacy and safety — not the economic evaluation. Each member state retains its own pricing and reimbursement authority. The regulation reduces duplicative clinical data submission requirements but does not create a single European price.
NICE (UK). NICE uses a cost-per-QALY framework with a conventional threshold of £20,000-£30,000 per QALY. Drugs that fall below the £30,000 threshold with standard evidence are routinely approved. Drugs above that threshold require an end-of-life modifier (available for drugs extending life by at least three months in a patient population with a short remaining life expectancy) or access through the Innovative Medicines Fund (formerly the Cancer Drugs Fund). NICE’s preferred evidence standard is a network meta-analysis anchoring the drug against the relevant UK standard of care, not just against placebo or best supportive care. Companies that design clinical trials without a UK standard-of-care comparator often find themselves building indirect treatment comparisons with high uncertainty ranges that NICE regards skeptically.
G-BA/IQWIG (Germany). Germany’s AMNOG process is the fastest formal HTA review in Europe — typically concluding 12 months after launch — but its outcome determines whether a drug achieves a ‘major additional benefit,’ ‘considerable additional benefit,’ ‘minor additional benefit,’ or ‘no additional benefit’ rating relative to the Appropriate Comparative Therapy (ACT) defined by G-BA. The ACT designation is determined before the drug launches, and if the drug’s clinical trial did not compare directly against the ACT, the benefit rating will be based on indirect comparisons or rejected outright. Germany’s ‘free pricing’ for the first year post-launch — allowing manufacturers to set any launch price — followed by mandatory negotiation with GKV-Spitzenverband (the national statutory health insurance federation) after the AMNOG assessment, creates a specific commercial dynamic: manufacturers generate high launch revenue in year one, then negotiate down. Drugs with ‘no additional benefit’ ratings face reference pricing at the level of the cheapest alternative, effectively eliminating any pricing premium.
HAS (France). France’s HAS conducts the Transparency Committee review, which rates a drug’s clinical benefit (SMR — Service Medical Rendu) and its degree of clinical improvement (ASMR — Amelioration du Service Medical Rendu) on a five-point scale. An ASMR I-III rating justifies a price premium over the existing standard of care. An ASMR IV (minor improvement) or ASMR V (no improvement demonstrated) results in reference pricing. France also operates a system of early access authorization (accès précoce) that allows use of drugs before formal HAS review, with manufacturers typically reimbursed at the requested price during this period, subject to a final price retroactively applied and rebated if the formal HAS assessment results in a lower price.
Italy and Spain: the access timeline problem. Both Italy and Spain require national HTA review, budget impact assessment, and regional-level reimbursement decisions before a drug is broadly available. The combined timeline from EMA approval to regional availability in Italy can exceed 24 months. Spain’s Dirección General de Cartera Básica de Servicios del SNS y Farmacia process is similarly extended. This timing gap has historically driven ‘managed entry agreements’ (MEAs) — conditional reimbursement schemes tied to patient outcomes data — that are negotiated with AIFA (Italy) or the Ministerio de Sanidad (Spain). MEAs reduce the payer’s risk of paying full price for a drug that underperforms in real-world use, but they require the manufacturer to build a post-launch data infrastructure that adds ongoing operational cost.
4.3 Value-Based Pricing: Architecture and Preconditions
Value-based pricing (VBP) ties the price of a drug to its real-world clinical outcomes. The concept is intuitive: a drug that cures a disease should cost more than one that only manages it, and the price should be calibrated to the health value delivered. In practice, VBP arrangements are complex, administratively burdensome, and appropriate only under specific conditions.
The preconditions for a viable VBP arrangement are narrow. The drug must have no generic alternatives whose price competition would undercut any value-based premium. The clinical outcomes must be clearly definable, measurable at reasonable cost, and attributable to the drug rather than confounded by concurrent therapies or patient adherence. The patient population must be large enough to justify the data infrastructure required to track outcomes at the individual patient level. And the payer must have both the technical capability to analyze the outcomes data and the contractual machinery to process rebate adjustments if outcomes fall below the agreed threshold.
The most established VBP arrangements in the U.S. are outcomes-based contracts between manufacturers and large commercial payers. Merck has operated outcomes-based contracts for Januvia and Janumet with Cigna. Novartis negotiated an outcomes-based contract for Entresto with several U.S. payers, tying rebates to reductions in heart failure hospitalization rates. Both arrangements required significant investment in data sharing infrastructure and have produced mixed results in terms of administrative efficiency. The transaction costs of running these programs — the actuarial modeling, the claims adjudication, the contractual dispute resolution — are non-trivial.
Indication-based pricing represents a related concept: charging different prices for the same drug depending on its approved indication. This model is theoretically attractive for drugs like pembrolizumab (Keytruda), which is approved for more than 15 oncology indications with widely varying clinical benefit profiles. In some indications, Keytruda generates overall survival benefits of several years. In others, the benefit is measured in weeks of progression-free survival. A single list price cannot accurately reflect this range of values. The operational challenge is that U.S. pharmacy systems are not designed to track the clinical indication for each dispensed unit, making indication-specific pricing administratively complex. The IRA’s MFP program, notably, applies to the drug as a whole rather than to specific indications, bypassing the indication-level pricing question.
4.4 Generic and Biosimilar Competition: The IRA’s Chilling Effect and the Math Behind Market Entry
The economic decision to develop a generic or biosimilar is a straightforward investment calculation. A generic filer must invest in bioequivalence studies, manufacturing scale-up to FDA standards, and legal defense of its Paragraph IV certification if the brand-side patents are challenged. The expected return on that investment depends on the price difference between the brand and the eventual generic, the total dispensed volume, and the number of other generic filers competing for the same market share.
The IRA’s MFP mechanism directly attacks the economics of this calculation. For a drug whose Medicare price has been negotiated to, say, 60% of its prior net price through the IRA, the addressable revenue opportunity for a generic or biosimilar competitor — who typically prices at 20-40% of the brand net price — shrinks proportionally. If the brand’s Medicare price is already $X through the MFP, a generic priced at 0.3X needs to capture more total volume to generate the same absolute return. In markets where the IRA has most aggressively compressed brand pricing, generic entry becomes economically marginal.
The Association for Accessible Medicines (AAM) has documented specific cases where this chilling effect is already influencing ANDA filing decisions. The economic analysis tracks: where the IRA’s MFP reduces the brand price significantly, the expected profit pool for generic market entry shrinks, and fewer companies file ANDAs. This creates a scenario where the Medicare patient population experiences modest price reduction from the MFP, but never experiences the 80-90% price reduction that broad generic competition would have produced. The long-term affordability outcome may be worse than under the pre-IRA system, where a brand drug at full price attracted aggressive generic competition that ultimately drove prices to near-commodity levels.
Biosimilar interchangeability is an additional access barrier worth detailing. Under the BPCIA, a biosimilar can receive a designation of ‘interchangeable’ from FDA if it demonstrates that patients can be switched between the reference product and the biosimilar without clinically meaningful differences, based on a switching study. An interchangeable biosimilar can be substituted at the pharmacy level without prescriber intervention in states that have enacted pharmacist substitution laws — the majority of states. A non-interchangeable biosimilar requires an explicit prescriber switch order. In practice, payers and PBMs drive the transition to biosimilars through formulary exclusion of the reference product, which achieves similar market share shifts regardless of interchangeability status. But biosimilar interchangeability matters commercially at the patient-prescriber interface, where habit and familiarity with the reference product are the primary inertia forces.
Key Takeaways — Section 4
Market access is not a post-approval function; it is a pre-clinical discipline. Trial designs that do not address the comparator questions asked by NICE, G-BA, or HAS will produce drugs that are approved but inadequately reimbursed in major European markets. The IRA’s chilling effect on generic competition is a policy design flaw with concrete market consequences: targeted government price cuts are crowding out the market competition that produces deeper, more durable price reductions.
Investment Strategy — Section 4
For investors modeling European revenue for pipeline assets, the HTA-specific evidence requirements for each target market must be incorporated into clinical trial design costs and timeline models. A NICE submission that requires a full network meta-analysis against the UK standard of care, built from a trial that used a non-standard comparator, will require a year of methodological work post-approval, delaying reimbursement and peak revenue. That delay has an NPV cost. For generic and biosimilar investors, the IRA’s impact on the addressable revenue pool for drugs in their development pipeline requires explicit modeling — particularly for drugs with upcoming IRA selection eligibility.
Section 5: Next-Generation Therapies and Novel Payment Architectures
5.1 Cell and Gene Therapy: The $2M+ Price Problem and Why Traditional Reimbursement Fails
The FDA has approved more than 30 cell and gene therapies (CGTs) as of early 2026, with prices ranging from $375,000 for Spinraza (nusinersen, Biogen) to approximately $3.5 million for Hemgenix (etranacogene dezaparvovec, CSL Behring/uniQure) for hemophilia B. These prices are not arbitrary; they reflect the cost-effectiveness framework that manufacturers use to justify pricing: if a one-time treatment eliminates a lifetime of factor VIII infusions at $500,000-$750,000 per year for hemophilia A, the math supports a multi-million dollar price in a standard QALY model.
The problem is not the math. The problem is the payment architecture. The traditional reimbursement system processes drugs as episodic claims: a prescription is dispensed, an adjudication occurs, payment is made. For a $3.5 million single treatment, this process creates an immediate, massive budget impact for the payer responsible at the time of treatment. In a U.S. commercial insurance market where the average beneficiary changes health plans every three to five years, the payer absorbing the $3.5 million upfront cost may lose that patient to a competitor plan within 18 months. The subsequent payers — who receive a healthy, treated patient requiring minimal medical care — capture the long-term financial benefit while bearing none of the treatment cost. This misaligned incentive creates a rational, if socially destructive, resistance to coverage among commercial plans.
Medicaid faces a related problem. Medicaid eligibility is episodic and income-based: a patient treated with a gene therapy for sickle cell disease (Casgevy from Vertex/CRISPR Therapeutics, priced at $2.2 million) may lose Medicaid eligibility as their income changes. CMS must pay the full treatment cost but may only capture the medical savings benefit for a fraction of the patient’s post-treatment years under Medicaid coverage.
Gene therapy technology roadmap. The current generation of approved CGTs uses adeno-associated virus (AAV) vectors for in vivo gene delivery and autologous lentiviral or retroviral vectors for ex vivo cell modification. AAV vector manufacturing is capacity-constrained and expensive, contributing to therapy costs that are likely irreducible below $1 million in the near term at current manufacturing scales. The next generation of delivery modalities — lipid nanoparticles (LNPs) for mRNA delivery, non-viral DNA delivery vehicles, and base editing technologies — may offer manufacturing cost profiles that bring one-time curative treatments below current AAV-based price floors. CRISPR-based gene editing (both in vivo and ex vivo) represents a platform technology with applications across multiple genetic diseases; the IP architecture around CRISPR foundational patents — contested between the Broad Institute and UC Berkeley in years of interference proceedings — remains one of the most complex freedom-to-operate environments in biotech.
5.2 Novel Payment Model Architecture: From Installment Plans to Subscription Models
Four primary payment models have emerged to address the misalignment between one-time CGT costs and multi-year benefit accrual.
Installment payment structures spread the total treatment cost across a defined period, typically three to five years, converting a capital event into an annuity. Manufacturers such as Spark Therapeutics (Luxturna, $850,000 for both eyes) have negotiated installment structures with commercial payers. The operational challenge is managing payment continuity if the patient changes health plans: the current payer owns the installment payment obligation for the treatment period, but if the patient transitions to a new plan, the original plan may argue it should no longer owe installments for a patient it no longer covers. Contractual clarity on installment persistence through patient transitions is an active area of legal negotiation.
Outcomes-based agreements (OBAs) tie payment to achieving predefined clinical milestones at specific post-treatment intervals. Novartis’s Zolgensma (onasemnogene abeparvovec, $2.1 million) has OBAs with several U.S. payers under which Novartis refunds a portion of the price if the treated patient fails to meet motor function milestones at defined time points. The administrative infrastructure required — defining the milestone biomarkers, establishing measurement protocols, creating claims adjudication pathways for rebate calculation — is substantial. Disputes over milestone attainment require pre-agreed arbitration mechanisms. Multiple manufacturers report that the transaction cost of administering OBAs for small patient populations approaches or exceeds the value of the rebate protection they provide.
Subscription models apply a population-level payment logic that is particularly suited to infectious disease cures or high-prevalence rare diseases. Louisiana and Washington state negotiated subscription arrangements for Hepatitis C direct-acting antivirals with AbbVie (Mavyret) and Gilead (Sovaldi/Harvoni) for their Medicaid populations: the state paid a flat annual fee for unlimited access to the drug for all eligible Medicaid patients, removing the per-patient cost barrier. The CMS Innovation Center’s Gene Therapy Access Model (GTAM), launched in 2024, represents the federal government’s attempt to apply a similar population-level payment logic to gene therapies, with CMS negotiating directly with manufacturers on behalf of state Medicaid programs. GTAM addresses the Medicaid eligibility discontinuity problem by having CMS absorb the payment risk.
Indication-based pricing contracts address the differential value problem for multi-indication drugs. A payer that covers a drug used for both a high-value oncology indication (with meaningful survival benefit) and a lower-value dermatology indication at the same list price is overpaying for the latter and potentially underpaying for the former. Linking the contracted price to the specific approved indication for each patient requires pharmacy claims data that carries the ICD-10 diagnosis code, which is becoming more consistently available as specialty pharmacy dispensing systems improve. This model is most advanced in the U.S. hospital pharmacy setting, where the indication is documented as part of the medication order.
5.3 AI in Contract Lifecycle Management and Negotiation Strategy
AI is not a future consideration for pharmaceutical contract management. It is operational at major companies across contract drafting, review, and analytics functions as of 2025. The applications break into three capability tiers with distinct current maturity levels.
Tier 1 — document automation and clause extraction. AI-powered contract lifecycle management (CLM) platforms — Evisort, Ironclad, Sirion, Lexion — apply natural language processing to ingest, classify, and extract structured data from executed contracts at scale. A pharmaceutical company with 40,000 active contracts across clinical trial agreements, supply arrangements, licensing deals, and distribution agreements can deploy these tools to auto-extract renewal dates, payment obligations, change-of-control provisions, and governing law clauses, creating a searchable contract database that previously required armies of paralegals. ThoughtRiver and similar pre-negotiation AI tools compare draft terms against a company’s negotiation playbook in near real time, flagging non-standard or high-risk clauses before a human negotiator reviews the document. Review speed improvements of 60-80% over manual review are documented in multiple platform case studies.
Tier 2 — negotiation analytics and market benchmarking. More sophisticated platforms integrate claims data, public deal databases, and historical negotiation outcomes to provide benchmarking intelligence before the negotiation begins. For PBM contract negotiators on the manufacturer side, AI tools can model the market share impact of different rebate tiers, identify formulary precedents for drugs with similar clinical profiles, and simulate PBM responses to proposed contract structures. For M&A deal teams, AI-powered due diligence platforms can analyze thousands of patent documents, clinical trial publications, and regulatory filings faster than any human team. Firms including Clarivate, Epiq, and specialized pharma AI vendors offer this capability.
Tier 3 — autonomous negotiation agents. Large language model-based AI agents that can conduct preliminary contract negotiation autonomously — generating and responding to counteroffers, flagging threshold terms that require human escalation — are in early commercial deployment as of 2025 in lower-complexity agreements such as confidentiality agreements and clinical trial site agreements. The pharmaceutical industry’s legal and compliance teams remain appropriately cautious about deploying autonomous AI agents in high-value, complex negotiations where context, relationship, and judgment are critical.
AI-specific contractual terms. When a pharmaceutical company contracts with a healthcare AI vendor — for drug discovery AI, clinical trial optimization, or formulary analytics — the contract must address novel IP and liability provisions. Who owns the training data used to develop the model? Does the vendor’s model improve as a result of training on the client’s proprietary clinical data, and if so, who owns that improvement? If an AI tool produces an erroneous drug-drug interaction prediction that influences clinical prescribing, what is the vendor’s liability exposure? These questions are not yet resolved by standard contract templates or regulatory guidance. The precedents being set in 2025-2026 AI vendor contracts will define the IP and liability landscape for healthcare AI for years.
Key Takeaways — Section 5
Cell and gene therapy pricing is not a market access problem; it is a payment infrastructure problem. The drugs can be priced cost-effectively; the systems through which they are reimbursed cannot process their payment logic. Installment structures, OBAs, and subscription models are partial solutions that require significant negotiating investment and legal infrastructure. AI-powered contract management is already demonstrating operational ROI in speed and accuracy of review; the next frontier is strategic intelligence tools that shift negotiating leverage toward the party with better data.
Investment Strategy — Section 5
CGT companies with late-stage assets should model the payer’s cash flow impact — not just the total therapy cost — before setting their launch pricing strategy. A therapy priced at $3.5 million payable upfront against one priced at $2.5 million payable in five annual installments will encounter structurally different payer resistance regardless of cost-effectiveness. For investors in CGT companies, the payment model negotiation is as consequential as the clinical trial outcome. A company with a Phase III-approved gene therapy but no executed payer contracts before launch is commercially exposed regardless of FDA approval. Governance of AI vendor contracts — particularly around training data ownership and IP in AI-generated outputs — is a due diligence item that M&A teams should add to their standard IP diligence checklist for any biotech with substantial AI partnerships.
Section 6: The Negotiator’s Playbook — Core Strategies from the Trenches
6.1 Mastering the BATNA: The Real Source of Power at Every Pharmaceutical Negotiation Table
The Best Alternative To a Negotiated Agreement (BATNA) is not a fallback position. It is the source of every confident concession and every credible threat at the negotiating table. A negotiator who does not know their BATNA is not negotiating; they are hoping. In pharmaceutical contexts — where a single negotiation outcome can determine whether a drug reaches patients in a given market, whether a company survives its patent cliff, or whether an acquisition closes at the right multiple — the BATNA must be developed with the same rigor as any other strategic asset.
The Harvard Business School framework on BATNAs in negotiation, developed by faculty including Guhan Subramanian and colleagues, identifies three distinct types of ‘no’ that every negotiator must understand and be prepared to deploy:
A tactical no rejects a specific offer in order to elicit a better one. It is a negotiating move, not a terminal decision. A manufacturer declining CMS’s initial MFP offer in the IRA process is deploying a tactical no — they intend to negotiate further, not to exit.
A ‘no to re-set’ is a strategic pause. The negotiating party withdraws temporarily to take actions outside the negotiation that improve their BATNA before re-engaging. A drug company that files an IPR petition against a competitor’s blocking patent before re-approaching a licensing negotiation has used a ‘no to re-set’ to shift the IP landscape in its favor.
A final no is the decision to walk away and pursue the BATNA. No major pharmaceutical company has walked away from an IRA negotiation by accepting the excise tax or Medicaid exclusion penalty — the BATNA of commercial catastrophe is too severe. But smaller biotechs negotiating licensing terms with large pharma partners regularly deploy final nos when their pipeline is strong enough to attract competing bidders.
Steve Holtzman’s strategy at Millennium Pharmaceuticals — calling six other potential partners simultaneously whenever one deal looked promising — is the most cited real-world example of proactive BATNA construction in pharmaceutical dealmaking. The psychological effect on the primary counterparty of knowing that the other side has active, credible alternatives changes the negotiation dynamic more than any specific tactical maneuver. Constructing a competitive bid environment before the formal negotiation is more valuable than any particular concession strategy deployed during it.
6.2 Information Architecture: Preparing to Win Before the Negotiation Starts
‘Information is a negotiator’s greatest weapon’ is not a platitude in this context. It is a specific operational claim. The party that arrives at a pharma negotiation with better data — on patent validity, on real-world clinical outcomes, on competitor pricing architecture, on the counterparty’s financial constraints — wins more on terms, more often, than the party relying on relationships and experience alone.
In M&A negotiations, the information asymmetry between buyer and seller is the central tactical battleground. The seller controls access to the data room. What goes in — and what is omitted — shapes the buyer’s due diligence findings, which in turn drive the purchase price and representations demanded. Sophisticated sellers curate the data room to present their IP estate in its strongest light, minimizing visible risk. Sophisticated buyers run parallel independent research — USPTO prosecution history downloads, PTAB petition monitoring, FDA Purple Book and Orange Book analysis, published literature searches — to identify risks the seller has not disclosed. The gap between what the seller chose to show and what independent research reveals is the negotiation leverage the buyer uses to adjust price or demand stronger warranties.
In payer negotiations, the manufacturer that arrives with a pre-built cost-effectiveness model, a budget impact analysis, and a real-world evidence package demonstrating outcomes in clinical practice starts from a fundamentally different position than one relying on the label’s Phase III data alone. HEOR teams that begin building the real-world evidence dossier at Phase II data readout — rather than after approval — give commercial teams the tools they need to lead the value conversation rather than respond to the payer’s price objections.
6.3 Understanding the Other Side’s Financial Constraints
Knowing what the counterparty wants on paper is not the same as understanding their binding constraints. In pharmaceutical negotiations, binding constraints are almost always financial or structural, not principled.
A PBM negotiating rebates is constrained by the performance guarantees it has given its health plan clients: it has committed to delivering a specified level of rebate savings relative to a benchmark. If a manufacturer’s drug is in a class where the PBM’s benchmark performance requires a 40% rebate, offering 35% — however generous by historical standards — will not clear the PBM’s internal approval threshold. The manufacturer who knows this threshold can calibrate its offer more precisely than one who is simply responding to stated demands.
A government payer operating under a fixed budget appropriation cannot offer risk-sharing arrangements that create multi-year contingent liabilities outside its current fiscal year authorization. This structural constraint is why CMS’s pilot programs for gene therapy access (GTAM) require specific legislative or waiver authorities rather than simple contracting flexibility. A manufacturer proposing an installment payment structure to Medicaid needs to understand the state’s appropriations process before designing the payment schedule.
A small biotech negotiating a licensing deal with Big Pharma is constrained by its cash runway. A partner who understands that the biotech has 12 months of cash remaining can structure a deal with a modest upfront payment and large downstream milestones — shifting most of the value capture to events that may never occur — and the biotech may have no practical choice but to accept. The biotech’s team that recognizes this vulnerability and uses the negotiation period to simultaneously advance their lead asset to a data readout — improving their BATNA — can shift the dynamic even within a compressed timeline.
6.4 Building Toward Durable Agreements: The Long-Term Cost of Short-Term Wins
Pharmaceutical partnerships — licensing deals, co-promotion agreements, supply arrangements — are not transactional; they run for years or decades. A negotiation outcome that extracts maximum short-term value at the cost of the counterparty’s ability to perform the agreement is a loss disguised as a win. A development partner who is underfunded because the licensor demanded too large an upfront fee will underinvest in clinical development. A supply partner who is squeezed below manufacturing cost will create quality shortcuts. The negotiator who optimizes for today’s term sheet at the expense of tomorrow’s relationship is not serving their organization’s long-term interests.
This principle has specific application in the IRA context. Manufacturers who have publicly attacked the legality and ethics of the negotiation process while simultaneously complying with it have sent a signal to CMS that they view the process as adversarial. This posture affects the technical quality of data submitted, the candor of negotiation meetings, and the political capital available for seeking future legislative modifications. A more constructive posture — engaging substantively with CMS’s evidence review process, providing complete and transparent data on R&D costs, accepting the existence of the program as a new operating reality — creates a foundation for the kind of policy dialogue that leads to program modifications that serve industry interests on a longer time horizon.
6.5 Forward Outlook: The Forces Reshaping the Negotiation Landscape Through 2030
The IRA’s negotiation scope expands to 20 drugs per year from 2028 and begins covering Part B drugs with 2028 applicability. The drugs likely in the 2027 selection pool include high-spend biologics in rheumatology and oncology that are approaching their 11-year eligibility window. CMS’s published selection criteria prioritize total Medicare gross expenditure, so products with large Medicare populations and high per-unit costs are the most exposed.
Tariff risk on pharmaceutical API imports is not a hypothetical concern as of early 2026. Approximately 80% of API manufacturing for drugs sold in the U.S. is sourced from China and India. Executive branch tariff authority has been deployed against both countries in trade disputes, and the pharmaceutical supply chain’s dependence on foreign API manufacturing is an explicit vulnerability that has drawn bipartisan attention in Congress. Tariffs on APIs or finished dosage forms would directly increase manufacturing costs, compressing margins on both branded and generic drugs and creating a new variable in every pricing negotiation.
The biosimilar interchangeability landscape will continue to evolve. The FDA’s approval of multiple interchangeable biosimilars for high-volume biologics — adalimumab, ustekinumab, aflibercept — creates the conditions for PBM-driven reference product exclusion that accelerates biosimilar market penetration beyond what prescriber inertia alone would produce. For brand manufacturers, defending market share against interchangeable biosimilars requires either a patient preference program (demonstrating that patients on the original product show better outcomes), a device differentiation strategy (auto-injectors or wearable pumps that biosimilar competitors have not matched), or an authorized biosimilar launched through a subsidiary.
AI-driven drug discovery is compressing pre-clinical timelines and reducing the cost per compound synthesized and tested. If the capitalized development cost of $2.23 billion per approved drug decreases materially over the next decade through AI acceleration, the traditional justification for high launch prices — recovering large R&D investments — becomes harder to sustain against payer pressure. This is a long-cycle dynamic, but it represents a structural change to the negotiation arguments that will be available to manufacturers by 2030.
Key Takeaways — Section 6
BATNA is built before the negotiation begins. Information preparation — IP landscape analysis, counterparty financial constraint mapping, real-world evidence package construction — determines the quality of the deal more than any tactic deployed at the table. Every short-term concession extracted at the cost of a counterparty’s operational capability is a long-term liability. The IRA’s expanding scope, biosimilar interchangeability momentum, and AI-driven development cost compression are the three structural forces that will most materially reshape pharmaceutical negotiation dynamics through 2030.
Investment Strategy — Section 6
For institutional investors, the drugs most exposed to IRA round 2027 and 2028 selections are identifiable today: filter the Medicare Part D gross spending database by drugs with no generic or biosimilar competition, approach their 11-year biologic or 7-year small-molecule windows, and carry high per-unit costs. Model the MFP using round one discount rates as a proxy. Overlay biosimilar pipeline data to identify which drugs face double exposure — IRA selection plus imminent interchangeable biosimilar entry. Assets exposed to both simultaneously, as J&J’s Stelara experienced, face the most severe revenue compression. Position accordingly.
Sources: Deloitte Annual Drug Development ROI Survey 2024; Drug Channels Institute Gross-to-Net Bubble Report 2025; Brookings Institution IRA Negotiation Analysis; CMS Medicare Drug Price Negotiation Program Fact Sheets; House Oversight Committee PBM Report 2024; FTC Pharmacy Benefit Manager Report 2024; IQVIA Biopharma M&A Outlook 2025; PwC Global M&A Health Industries Outlook 2025; Foundation for Research on Equal Opportunity IRA Innovation Impact Analysis; Association for Accessible Medicines Chilling Effect Analysis; HBS ‘BATNAs in Negotiation: Common Errors and Three Kinds of No’; DrugPatentWatch M&A Patent Due Diligence Comprehensive Guide; KFF IRA Medicare Negotiation FAQs.
